🚀 VC round data is live in beta, check it out!
Bio-Thera Solutions Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bio-Thera Solutions and similar public comparables like Eczacıbaşı İlaç, Maze Therapeutics, SOTHEMA, Corvus Pharma and more.
Bio-Thera Solutions Overview
About Bio-Thera Solutions
Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail.
Founded
2003
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$1B
Bio-Thera Solutions Financials
Bio-Thera Solutions reported last fiscal year revenue of $109M and negative EBITDA of ($59M).
In the same fiscal year, Bio-Thera Solutions generated $75M in gross profit, ($59M) in EBITDA losses, and had net loss of ($75M).
Bio-Thera Solutions P&L
In the most recent fiscal year, Bio-Thera Solutions reported revenue of $109M and EBITDA of ($59M).
Bio-Thera Solutions expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $109M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $75M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 69% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($59M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (54%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (67%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($75M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (69%) | XXX | XXX | XXX |
| Net Debt | — | — | $25M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bio-Thera Solutions Stock Performance
Bio-Thera Solutions has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Bio-Thera Solutions' stock price is $3.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -1.8% | XXX | XXX | XXX | $-0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBio-Thera Solutions Valuation Multiples
Bio-Thera Solutions trades at 13.3x EV/Revenue multiple, and (24.8x) EV/EBITDA.
Bio-Thera Solutions Financial Valuation Multiples
As of April 18, 2026, Bio-Thera Solutions has market cap of $1B and EV of $1B.
Equity research analysts estimate Bio-Thera Solutions' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bio-Thera Solutions has a P/E ratio of (18.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (24.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (20.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 19.3x | XXX | XXX | XXX |
| P/E | — | XXX | (18.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (54.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bio-Thera Solutions Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bio-Thera Solutions Margins & Growth Rates
Bio-Thera Solutions' revenue in the last fiscal year grew by 5%.
Bio-Thera Solutions Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (54%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 34% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 105% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 136% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bio-Thera Solutions Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bio-Thera Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Eczacıbaşı İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Maze Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SOTHEMA | XXX | XXX | XXX | XXX | XXX | XXX |
| Corvus Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Precigen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bio-Thera Solutions M&A Activity
Bio-Thera Solutions acquired XXX companies to date.
Last acquisition by Bio-Thera Solutions was on XXXXXXXX, XXXXX. Bio-Thera Solutions acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bio-Thera Solutions
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBio-Thera Solutions Investment Activity
Bio-Thera Solutions invested in XXX companies to date.
Bio-Thera Solutions made its latest investment on XXXXXXXX, XXXXX. Bio-Thera Solutions invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bio-Thera Solutions
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bio-Thera Solutions
| When was Bio-Thera Solutions founded? | Bio-Thera Solutions was founded in 2003. |
| Where is Bio-Thera Solutions headquartered? | Bio-Thera Solutions is headquartered in China. |
| Is Bio-Thera Solutions publicly listed? | Yes, Bio-Thera Solutions is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Bio-Thera Solutions? | Bio-Thera Solutions trades under 688177 ticker. |
| When did Bio-Thera Solutions go public? | Bio-Thera Solutions went public in 2020. |
| Who are competitors of Bio-Thera Solutions? | Bio-Thera Solutions main competitors are Eczacıbaşı İlaç, Maze Therapeutics, SOTHEMA, Corvus Pharma. |
| What is the current market cap of Bio-Thera Solutions? | Bio-Thera Solutions' current market cap is $1B. |
| What is the current revenue of Bio-Thera Solutions? | Bio-Thera Solutions' last fiscal year revenue is $109M. |
| What is the current EV/Revenue multiple of Bio-Thera Solutions? | Current revenue multiple of Bio-Thera Solutions is 13.3x. |
| Is Bio-Thera Solutions profitable? | No, Bio-Thera Solutions is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.